Digital Library / STP / STP1466-EB / STP45222S

The Role of TGA-DTA in the Initial Evaluation of the Solid State Forms for Pharmaceutical New Chemical Entities, Part 1: Evaluation of Pure Forms
Redman-Furey, Nancy L.
Principal Scientist, P&G Pharmaceuticals, Inc., New York

Dicks, Michael L.
Principal Researcher, P&G Pharmaceuticals, Inc., New York

Godlweski, Jane
Senior Researcher, P&G Pharmaceuticals, Inc., New York

Vaughn, Dana C.

Collins, Wendy J.

Pages: 10    Published: Jan 2007

Download this paper for $25 PDF (328K)          View License Agreement
        Click here to download the complete source publication for $55 PDF (4.2M)

Source: STP1466-EB

Abstract

TGA-DTA plays a central role in the strategy outlined for early evaluation of the solid state forms available to pharmaceutical new chemical entities. At this early stage of development, compound and time are typically at a premium, so a successful strategy requires making the best possible use of the materials and time available. In addition, because of time and compound limitations, the goal of a solid state investigation is focused upon early stage objectives rather than development of a complete understanding of all available solid state forms. The TGA-DTA is well suited to addressing these needs.

Keywords:
TGA, DTA, hydrate, thermal analysis, hygroscopicity, pharmaceutical

Paper ID: STP45222S
Committee/Subcommittee: E37.01
DOI: 10.1520/STP45222S
ASTM International is a member of CrossRef.